Molecular mimicry and cancer vaccine development.
Cancer Vaccines
Microbiota
Molecular Mimicry
T cell cross-reactivity
Tumor-Associated Antigens
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
26 04 2023
26 04 2023
Historique:
received:
22
02
2023
accepted:
14
04
2023
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
epublish
Résumé
The development of cancer immunotherapeutic strategies relies on the identification and validation of optimal target tumor antigens, which should be tumor-specific as well as able to elicit a swift and potent anti-tumor immune response. The vast majority of such strategies are based on tumor associated antigens (TAAs) which are shared wild type cellular self-epitopes highly expressed on tumor cells. Indeed, TAAs can be used to develop off-the-shelf cancer vaccines appropriate to all patients affected by the same malignancy. However, given that they may be also presented by HLAs on the surface of non-malignant cells, they may be possibly affected by immunological tolerance or elicit autoimmune responses. In order to overcome such limitations, analogue peptides with improved antigenicity and immunogenicity able to elicit a cross-reactive T cell response are needed. To this aim, non-self-antigens derived from microorganisms (MoAs) may be of great benefit.
Sections du résumé
BACKGROUND
The development of cancer immunotherapeutic strategies relies on the identification and validation of optimal target tumor antigens, which should be tumor-specific as well as able to elicit a swift and potent anti-tumor immune response. The vast majority of such strategies are based on tumor associated antigens (TAAs) which are shared wild type cellular self-epitopes highly expressed on tumor cells. Indeed, TAAs can be used to develop off-the-shelf cancer vaccines appropriate to all patients affected by the same malignancy. However, given that they may be also presented by HLAs on the surface of non-malignant cells, they may be possibly affected by immunological tolerance or elicit autoimmune responses.
MAIN BODY
In order to overcome such limitations, analogue peptides with improved antigenicity and immunogenicity able to elicit a cross-reactive T cell response are needed. To this aim, non-self-antigens derived from microorganisms (MoAs) may be of great benefit.
Identifiants
pubmed: 37101139
doi: 10.1186/s12943-023-01776-0
pii: 10.1186/s12943-023-01776-0
pmc: PMC10131527
doi:
Substances chimiques
Cancer Vaccines
0
Antigens, Neoplasm
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
75Informations de copyright
© 2023. The Author(s).
Références
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Science. 2016 Jun 10;352(6291):1337-41
pubmed: 27198675
Cell. 1996 Feb 23;84(4):521-9
pubmed: 8598039
J Exp Med. 1996 Aug 1;184(2):647-57
pubmed: 8760818
J Autoimmun. 2022 Dec 2;:102962
pubmed: 36470769
Science. 1992 Mar 6;255(5049):1261-3
pubmed: 1546328
Front Oncol. 2022 Oct 18;12:1009247
pubmed: 36330482
Annu Rev Immunol. 2006;24:419-66
pubmed: 16551255
Mol Immunol. 2004 Feb;40(14-15):1047-55
pubmed: 15036909
J Exp Med. 2002 Jul 15;196(2):207-16
pubmed: 12119345
J Transl Med. 2021 Dec 24;19(1):526
pubmed: 34952611
Nat Immunol. 2009 Feb;10(2):143-7
pubmed: 19148199
Cell. 2019 Aug 8;178(4):795-806.e12
pubmed: 31398337
Science. 2002 Oct 25;298(5594):850-4
pubmed: 12242449
JCI Insight. 2020 Apr 23;5(8):
pubmed: 32324171
Lancet Infect Dis. 2010 May;10(5):305-16
pubmed: 20417413
J Exp Med. 1997 Mar 3;185(5):833-41
pubmed: 9120389
Immunity. 2021 Mar 9;54(3):586-602.e8
pubmed: 33691136
Annu Rev Immunol. 2019 Apr 26;37:173-200
pubmed: 30550719
Proc Natl Acad Sci U S A. 1955 Nov 15;41(11):849-57
pubmed: 16589759
Nat Immunol. 2005 Nov;6(11):1114-22
pubmed: 16186824
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Science. 1996 Aug 16;273(5277):963-6
pubmed: 8688082
Science. 2020 Aug 21;369(6506):936-942
pubmed: 32820119
Immunol Today. 1998 Sep;19(9):395-404
pubmed: 9745202
Mol Med. 2002 Mar;8(3):115-9
pubmed: 12142543
J Transl Med. 2022 Jul 14;20(1):316
pubmed: 35836198
Nat Med. 2022 Mar;28(3):545-556
pubmed: 35228752
J Transl Med. 2022 Oct 15;20(1):472
pubmed: 36243758
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10608-13
pubmed: 20483993
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6796-806
pubmed: 18006782
J Exp Med. 1999 Sep 6;190(5):705-15
pubmed: 10477554
Lancet. 1962 Apr 7;1(7232):706-10
pubmed: 14453769
Cancers (Basel). 2021 Dec 28;14(1):
pubmed: 35008303
HIV Med. 2013 Sep;14(8):481-90
pubmed: 23560682
Nat Med. 2022 Mar;28(3):535-544
pubmed: 35228751
Semin Immunol. 2007 Aug;19(4):216-24
pubmed: 17398114
J Autoimmun. 2018 Dec;95:100-123
pubmed: 30509385
Immunogenetics. 1999 Nov;50(3-4):213-9
pubmed: 10602881
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Anticancer Drugs. 2016 Apr;27(4):269-77
pubmed: 26813865
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
J Immunol. 1992 Dec 1;149(11):3580-7
pubmed: 1331239
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
J Transl Med. 2021 Feb 26;19(1):89
pubmed: 33637105
Clin Vaccine Immunol. 2011 Jan;18(1):23-34
pubmed: 21048000
J Transl Med. 2018 Oct 19;16(1):286
pubmed: 30340600
J Immunol. 2002 Nov 15;169(10):5696-707
pubmed: 12421949
Immunity. 1997 Aug;7(2):179-86
pubmed: 9285403
Vaccines (Basel). 2020 Oct 17;8(4):
pubmed: 33080888
Cell. 1997 Mar 7;88(5):627-36
pubmed: 9054502
Semin Oncol. 2015 Apr;42(2):247-57
pubmed: 25843729
Science. 1999 Oct 29;286(5441):958-61
pubmed: 10542151
Curr Opin Immunol. 1996 Dec;8(6):878-85
pubmed: 8994870
J Immunother Cancer. 2021 May;9(5):
pubmed: 34049932
Immunogenetics. 1995;41(4):178-228
pubmed: 7890324
Expert Opin Biol Ther. 2003 Sep;3(6):985-93
pubmed: 12943457
Front Immunol. 2021 Oct 20;12:769799
pubmed: 34745146
Nature. 2011 May 12;473(7346):174-80
pubmed: 21508958
J Natl Cancer Inst. 2002 Jun 5;94(11):805-18
pubmed: 12048268
J Exp Med. 1996 Oct 1;184(4):1259-68
pubmed: 8879197
Oncoimmunology. 2014 Nov 14;3(8):e954501
pubmed: 25960935
Eur J Immunol. 1971 Jan;1(1):1-9
pubmed: 14978855
Br J Cancer. 2006 Feb 13;94(3):446-9
pubmed: 16404433